Rapamycin (sirolimus) and longevity in Germany

Rapamycin (sirolimus) is a prescription immunosuppressant, not a supplement. It is the most reliable life-extender in animal studies (mean lifespan +9% to +13% in mice ^[1]) because it blocks the mTOR nutrient switch, but it carries real immune-suppressing risks and has no proven longevity benefit in humans yet.

Rapamycin and sirolimus are two names for the same molecule. It came from a soil bacterium called Streptomyces hygroscopicus, found on Easter Island (Rapa Nui). The FDA approved it in 1999 as the immune-suppressing drug Rapamune. Wyeth-Ayerst made it, and Pfizer took it over when it bought Wyeth in October 2009. Europe gave it an EU-wide green light on 13 March 2001 ^[6]. Its first job was simple: calm the immune system down after a kidney transplant.

So how does it work? Rapamycin blocks a protein switch called mTOR (think of it as a sensor that checks whether your cells are flush with nutrients), and one version in particular, mTORC1. That switch runs cell growth, protein building, and autophagy (your cells cleaning out their own junk).

Why the longevity crowd is so into it: in animals, nothing else stretches lifespan this reliably. A 2009 Nature paper from the NIH Interventions Testing Program (ITP) started mice on microencapsulated rapamycin late, at 600 days of age. They still lived longer: mean lifespan went up +9% in males and +13% in females ^[1]. Other rodent ITP runs and separate cohorts point the same way, and so does work on TOR (the animal version of mTOR) in fruit flies (Drosophila) and roundworms (C. elegans). The effect shows up across species, even if it stays modest and strain-dependent in the tiny invertebrates.

Because rapamycin genuinely suppresses the immune system and brings other side effects, any off-label use carries real risk.

This guide is not medical advice.

mTOR matters for aging because it is the nutrient switch that decides whether cells grow or repair. Keep it switched on for too long and cells stop cleaning house. Autophagy stalls, senescent cells (old cells that refuse to die) pile up and aging seems to speed up. Rapamycin turns mTOR down directly, which is why it extends lifespan in mice (mean +9% to +13% ^[1]).

The whole mTOR longevity story rests on one simple chain of logic:

1. mTOR is an old nutrient sensor. It flips on whenever real food is around. Eat a lot, and it stays switched on.
2. Keep mTOR high for too long and aging seems to speed up. It shuts down autophagy (the cell's cleanup crew) and lets these zombie cells pile up, where they keep stoking low-grade inflammation.
3. Anything that turns mTOR down stretches animal lifespan. Eat less, fast, or take rapamycin.
4. Rapamycin is the most direct way to turn it down. You set a dose schedule instead of having to white-knuckle a diet for the rest of your life.

What the mouse studies found (NIH Interventions Testing Program):

• Give older mice rapamycin and they live longer. Mean lifespan went up about 9% in males and 13% in females, and the longest-lived 10% (the 90th percentile) gained about 9% in males and 14% in females, even when treatment started late ^[1]. That popular 14% figure for females is the 90th-percentile number, close to maximum lifespan. The matching mean is 13%.
• The effect showed up at all three independent ITP labs, in a genetically mixed mouse stock ^[1]. That is a big deal. Most rodent longevity wins quietly collapse the moment another lab repeats them.
• More dose, bigger effect: at a threefold higher dose, median lifespan rose 23% in males and 26% in females ^[11].

What stays open for people:

• We already age 30 to 50 times slower than mice. So a 15 percent gain on a 2-year mouse life does not magically become 15 percent on 80 human years.
• Damping the immune system at age 70, while normal infections circulate, is a real and ongoing worry even at weekly doses.
• Daily versus once a week? Newer protocols use low weekly doses to soften the immune hit, but the evidence behind that schedule is still thin.

No human trial has shown rapamycin extends life or healthspan. The longest longevity trial so far, PEARL (2025), missed its main goal of cutting visceral fat. It only turned up secondary signals, mostly in small subgroups ^[5]. The human evidence is far thinner than the animal record and rests on short trials of stand-in markers, not on how long people actually live.

The trials that aimed at longevity directly:

• The PEARL study ran for 48 weeks in healthy adults aged 50 to 85. It was randomized and placebo-controlled (some people got a dummy pill), testing rapamycin at 5 mg and 10 mg weekly. AgelessRx ran it, Lifespan.io crowdfunded it (trial ID NCT04488601), and it came out in April 2025 in Aging (Albany NY). 114 people finished it ^[5]. One catch: they used compounded rapamycin, mixed by a pharmacy instead of the brand-name tablet. The authors found it reaches only about a third of the blood levels of brand-name Rapamune. So the real doses were roughly 1.7 and 3.3 mg of the brand drug ^[5]. The endpoint they had committed to up front was a drop in visceral fat (the deep belly fat around your organs) on a DEXA scan. They did not hit it. The wins that did show up were secondary: more lean tissue and less self-reported pain in the women on 10 mg (only 8 women in that group), plus better self-rated well-being and general health on 5 mg ^[5]. Small subgroups like these are hints, not proof.
• The lower-dose immune trials. Several related studies in older adults tested whether gently turning mTOR down could improve immune function. The 2014 one (Sci Transl Med) tested everolimus on its own (also called RAD001, a close cousin of rapamycin), at doses from 0.5 mg daily up to 20 mg weekly ^[2]. The 2018 one (also Sci Transl Med) was a small phase 2a trial in 264 older adults over 6 weeks. A low-dose combo of RTB101 (a newer experimental TORC1 blocker, then called BEZ235) plus everolimus came with fewer reported infections over the next year ^[3]. A larger phase 2b trial (652 people) then tested RTB101 alone or with everolimus 0.1 mg. Only one arm (dose group), RTB101 10 mg once daily, hit its prespecified goal. The twice-daily dose and the combo did not ^[4]. The phase 3 follow-up (1,024 people) in Lancet Healthy Longevity (2021) failed to repeat that benefit, and that ended the RTB101 immune-boosting program ^[4]. This flop is about RTB101, not rapamycin itself.

What we see in transplant patients:

• People switched to rapamycin after a kidney transplant get fewer new skin cancers ^[8], and a pooled analysis of 21 trials also found fewer cancers overall ^[10].
• The same pooled analysis found a higher risk of death on sirolimus ^[10]. In the skin-cancer trial, about 1 in 4 people stopped the drug because of side effects ^[8].
• These are people already on heavy immune suppression, so it does not map cleanly onto longevity use in an otherwise healthy adult.

In PEARL, side effects, including serious ones, were about as common on rapamycin as on placebo over 48 weeks ^[5]. That says little about 10-plus years of use.

The side effects you see most at longevity doses (6 mg per week was the most common dose in a survey of 333 off-label users ^[9]):

• Mouth ulcers. The only problem clearly more common in users than non-users in that survey ^[9]. A topical dexamethasone mouthwash can help.
• Occasional signs of a softened immune response, like minor infections that linger or come back more often
• Higher blood fats (triglycerides and LDL)
• Higher blood sugar
• Proteinuria (protein leaking into urine, a classic kidney issue in transplant patients). Rare at weekly longevity doses, but still tracked with a urine ACR test.
• Slower wound healing. Pause rapamycin at least two weeks before any planned surgery and only restart once the wound has fully healed.
• Pneumonitis or interstitial lung disease (inflammation in the lungs). Uncommon, but it is listed in the official drug label (the SmPC). A new dry cough or shortness of breath needs urgent checking.
• Interactions with a lot of drugs, all running through one liver enzyme called CYP3A4

Hard nos and serious cautions:

• Pregnancy and breastfeeding. In animal studies rapamycin harms the developing fetus: fetal death and lower fetal weight, though no structural malformations were seen. Based on those findings and how the drug works, it can harm a human fetus too. You need effective contraception during treatment and for 12 weeks after you stop.
• Live vaccines (yellow fever, MMR, varicella, nasal flu) are off-limits while on rapamycin, so finish any travel shots you need before you start, or during a planned break.
• Recent or upcoming surgery. See the wound-healing note above.
• Active infection or an open wound. Pause until it clears.

What we genuinely still do not know:

• Whether it is safe over 10-plus years in healthy adults
• The best dose and schedule
• Who actually benefits

Short answer: yes, rapamycin (sirolimus) is an approved medicine in Germany, but only for a few specific jobs:

• Rapamune tablets: preventing rejection after a kidney transplant ^[6]
• Rapamune tablets: lymphangioleiomyomatosis (LAM, a rare lung disease) ^[6]
• Hyftor gel (since 2023): facial skin growths (angiofibromas) in tuberous sclerosis complex, a rare genetic disease ^[12]

Doctors also use it off-label for some vascular malformations. Longevity is not on any list. Any prescription written for it counts as off-label. That is legal, but it puts more liability on the doctor and means they have to counsel you more carefully than usual.

What this looks like in real life:

• Your statutory health insurance won't pay. It only covers rapamycin for approved uses, so for longevity you get a private prescription and pay 100 percent yourself.
• The cost adds up fast. At the official pharmacy price (Apothekenverkaufspreis, AVP), the cheapest pack of 100 Rapamune 1 mg tablets (a parallel import) costs €1,185.61, about €11.86 per tablet. The Pfizer original is €1,211.46 (checked September 2026) ^[13]. At 5 to 6 mg per week, that is roughly €257 to 308 per month.
• Finding a prescriber is the hard part. You need a doctor willing to go off-label, and in Germany very few practices do. In the US, online longevity clinics prescribe it. In Germany, few if any telemedicine services do, and an online script still needs a real consultation with a doctor.
• Advertising rules (HWG). Prescription drugs may not be advertised to the public at all (§10 HWG), and advertising an unapproved use like longevity is banned on top of that (§3a HWG).

Pharmacy prices for Rapamune in Germany (September 2026) ^[13]:

What about ordering it from outside the EU/EEA (India, Turkey)? Mailing prescription medicines from non-EU/EEA countries to private individuals is banned under §73 of the German medicines act (Arzneimittelgesetz, AMG). This is not a grey zone ^[7]. German Customs (Zoll) checks international mail all the time and seizes these parcels. Recipients can face a fine (it is an administrative offence under §97 AMG), and counterfeit drugs can trigger a criminal case. There is a separate, narrow exception: a traveller may carry the usual personal supply (customs generally treats about 3 months as the limit) in their own luggage when entering Germany ^[7]. That does not cover anything sent by post. And even if a package slips through, you get zero quality control. Not recommended.

For NMN and other grey-zone questions, see the NMN Germany guide.

Talk to a doctor who knows rapamycin and will monitor you with regular labs, never your GP without specific training. Come with your current markers, your medication list, and a clear sense of the risk you will carry. Good prescribers ask their own questions and agree on stop criteria up front; anyone who prescribes without any of that is the wrong partner.

This guide gives no dosing advice. The eligibility points and lab numbers below are things to talk through with the doctor who would prescribe it, not thresholds you manage on your own. Off-label rapamycin needs individual medical supervision and your informed consent.

Green-light and red-light signals:

Probably not a fit if you:

• get infections often or have a weakened immune system
• have surgery planned in the next 6 months
• run an uncontrolled HbA1c (a 3-month blood-sugar average) above 6.5%
• have LDL-C (your bad cholesterol) above 160 mg/dL
• are being treated for active cancer
• are pregnant, nursing, or planning to get pregnant within 12 months
• are under 45 without a specific fast-aging profile

Possibly a fit if you:

• are 55 or older and metabolically healthy, with LDL-C and HbA1c in range
• have no surgeries on the calendar
• are willing to pause for any acute infection
• have a doctor available for quarterly checks
• go in knowing this is off-label and the evidence is still light

Which doctor to ask. Very few German Hausärzte (GPs) will write an off-label rapamycin script, so skip your regular GP unless they have specific training. Better bets:

• Internal-medicine specialists with a prevention or longevity focus, ideally with the Zusatzbezeichnung Naturheilverfahren or Ernährungsmedizin. These are the two formal add-on qualifications from the German Medical Association (BÄK) that fit here. "Präventivmedizin" is only a continuing-education course, not a Zusatzbezeichnung.
• Dedicated longevity private practices in Munich, Berlin, Hamburg, Frankfurt, Vienna, Zurich

To search, try arzt-auskunft.de with the right Zusatzbezeichnung filter, or the Ärztekammer Bayern, ÖÄK, or FMH directories. Plan for €200 to 500 for a first self-pay (Selbstzahler) visit.

The CYP3A4 interactions worth knowing (these are everyday traps). CYP3A4 is the liver enzyme that clears rapamycin. Anything that blocks it pushes your levels up. Anything that revs it up drops them.

• Grapefruit, as juice or as fruit: blocks the enzyme, so your levels rise.
• St. John's wort and rifampicin: both rev the enzyme up and drop your levels. Rifampicin is the textbook example, relevant if you are on TB treatment or some staph prophylaxis.
• Clarithromycin or erythromycin (antibiotics), ketoconazole or itraconazole (antifungals), diltiazem or verapamil (blood-pressure and heart-rhythm drugs): steer clear.
• Statins: many need a dose tweak alongside rapamycin.

Always hand your pharmacist and doctor a full list of what you take, including over-the-counter and herbal stuff.

The lab schedule if you are on off-label rapamycin:

• At baseline: a full blood count (CBC), a metabolic panel (CMP: kidney and liver values plus electrolytes), fasting lipids, HbA1c, fasting glucose, lipase, a urine ACR (checks for protein in urine), vitamin D, blood pressure, and a TB screen.
• At week 4: recheck the blood count, metabolic panel, fasting glucose, lipids, and lipase.
• Then every quarter: the same labs.

When to stop:

• a neutrophil count (ANC, a type of white blood cell) below 1.5 x10^9/L (1,500 cells per microlitre)
• new protein in the urine
• triglycerides above 500 mg/dL (about 5.6 mmol/L)
• HbA1c more than 0.5 percentage points above your baseline
• mouth ulcers that won't quit despite dose changes
• any active infection (pause until it clears)

A note on women's health. Rapamycin (sirolimus) used to sit in the old FDA Pregnancy Category C, because animal studies showed harm to the developing fetus (fetal death and lower fetal weight, not structural malformations). The FDA scrapped that A/B/C/D/X letter system in 2015 under the Pregnancy and Lactation Labeling Rule (PLLR). Today's Rapamune label uses a plain-language 'Risk Summary' instead. It says the drug can harm a fetus, based on the animal data and how it works. You need effective contraception during treatment and for 12 weeks after stopping. Not for nursing mothers. There is no longevity reason that justifies rapamycin in pregnancy or breastfeeding, full stop.

Before you go in, get clear on:

• Your current markers (blood panel, heart and blood vessel risk, metabolic profile)
• Any drugs you take that clash with rapamycin (the CYP3A4 list)
• Any current or chronic infections
• How much risk you are personally willing to carry

Fair questions to put to the doctor:

1. Do you know the current longevity data on rapamycin?
2. Are you willing to prescribe off-label and document it properly?
3. Which lab values would you track?
4. How often should I come back for check-ins?
5. What would make you stop treatment?

A doctor who brushes off these questions is the wrong partner. So is one who will prescribe without asking any of their own.